Navigation Links
Nuvelo Announces Presentation on rNAPc2 at American College of,Cardiology 56th Annual Scientific Session

SAN CARLOS, Calif., March 19, 2007 /PRNewswire-FirstCall/ -- Nuvelo, Inc. today announced that clinical data from the ANTHEM (Anticoagulation with rNAPc2 To Help Eliminate MACE)/TIMI 32 Phase 2 trial looking at recombinant nematode anticoagulant protein c2 (rNAPc2) in patients with non-ST-elevation acute coronary syndromes (NSTE-ACS) will be presented in a V-poster presentation at the of Cardiology (ACC) 56th Annual Scientific Session taking place in New Orleans, LA, March 24-27, 2007.

    The presentation details are as follows:


    Date/Time: Monday, March 26, 2007, 12:00 - 1:00 p.m. CDT


    Presentation Number: 1202-252


    Abstract Title: Safety and Tolerability of a Novel Tissue Factor/Factor

    VIIa Inhibitor rNAPc2 in Patients With Non-ST-Elevation Acute Coronary

    Syndrome Managed Invasively: Results From the ANTHEM/TIMI 32 Trial


    About V-Posters: V-posters are narrated by a prerecorded expert commentary

    and can be accessed by cell phone as attendees view the poster. The

    posters will remain on display for the entire length of the meeting.


    About Nuvelo

Nuvelo, Inc. is dedicated to improving the lives of patients through the discovery, development and commercialization of novel drugs for acute cardiovascular and cancer therapy. Nuvelo's development pipeline includes three acute cardiovascular programs: alfimeprase, a direct-acting thrombolytic for the treatment of thrombotic-related disorders which is suspended pending review and analysis of clinical data; rNAPc2, an anticoagulant that inhibits the factor VIIa and tissue factor protease complex that completed Phase 2 clinical development in acute coronary syndromes; and preclinical candidate NU172, a direct thrombin inhibitor for use as a short-acting anticoagulant during medical procedures. Nuvelo is also advancing an emerging oncology pipeline, including rNAPc2 which is in Phase 2 testing for potential
'"/>




Page: 1 2 3

Related medicine technology :

1. Nuvelo Announces Presentations on rNAPc2 and NU172 at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. Nuvelo Announces Publication of Phase 2 rNAPc2 Study Results in Journal of American College of Cardiology
3. Nuvelo Announces Publication of Preclinical Study Results Demonstrating the Potential of NTB-A as a New Target for Leukemia and Lymphomas
4. Nuvelo Announces Publication of NU206 Study Results in Gastroenterology
5. Nuvelo Announces Presentation on NU206 at 2007 American Association for Cancer Research Annual Meeting
6. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
7. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
9. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
10. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
11. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis

Post Your Comments:
(Date:11/24/2009)...INE, Calif., Nov. 24 End...lly invasive treatments for aortic disorders, anno... discontinue all proceedings in, the patent infrin...by Cook, Inc. The motion was filed in the United ..., Endologix has requested that the stay remain i...
(Date:11/24/2009)...MONT, Calif., Nov. 24 Ve...ed the Company filed its Plan of Reorganization an...ith the United States Bankruptcy Court for the Dis...of the Disclosure Statement is presently scheduled...firmation of the Plan scheduled for January 7, 201...
(Date:11/24/2009)...OODCLIFF LAKE, N.J. and NEW YORK, Nov. 24 /PRNewsw...y that the U.S. Food and Drug Administration (FDA)...ion (NDA) for once daily 23 mg Aricept® (done...ent of moderate to severe Alzheimer,s disease (AD)... of donepezil HCl in an extended release, matrix-t...
Breaking Medicine Technology:Endologix Files Motion to Discontinue Court Proceedings Related to Alleged Patent Infringement 2Vermillion Files Plan of Reorganization 2Vermillion Files Plan of Reorganization 3Vermillion Files Plan of Reorganization 4FDA Accepts Once Daily 23 mg Aricept(R) Extended Release NDA for Review 2FDA Accepts Once Daily 23 mg Aricept(R) Extended Release NDA for Review 3Digitas Health Expands Adding Two Key Locations 13208 1Digitas Health Expands Adding Two Key Locations 13208 2Digitas Health Expands Adding Two Key Locations 13208 3Digitas Health Expands Adding Two Key Locations 13208 4Kaiser Permanente to Provide Calorie Nutrition Information on Cafeteria Menus 52771 1Kaiser Permanente to Provide Calorie Nutrition Information on Cafeteria Menus 52771 2Kaiser Permanente to Provide Calorie Nutrition Information on Cafeteria Menus 52771 3Kaiser Permanente to Provide Calorie Nutrition Information on Cafeteria Menus 52771 4Access Pharmaceuticals Announces Commercial Launch of MuGard 28TM 29 in Norway by SpePharm 52769 1Access Pharmaceuticals Announces Commercial Launch of MuGard 28TM 29 in Norway by SpePharm 52769 2Access Pharmaceuticals Announces Commercial Launch of MuGard 28TM 29 in Norway by SpePharm 52769 3Access Pharmaceuticals Announces Commercial Launch of MuGard 28TM 29 in Norway by SpePharm 52769 4
... Stenting Safe and Effective in Patients f...ry, WASHINGTON, Sept. 1 Data announced today fro... with very complex coronary,artery disease can saf...-eluting stents rather than open-heart surgery, sa...Interventions (SCAI). The one-year results,of SYNT...
...n recent,concern that suicide may be a complicatio...is a Food and Drug Administration (FDA) approved o...decade for the treatment of,asthma and seasonal al...the,American Lung Association has found no evidenc... American Lung Association researchers Janet Holb...
Other Medicine Technology:SCAI: SYNTAX Data Show PCI Is a Good Option for Patients With Complex Coronary Artery Disease 2SCAI: SYNTAX Data Show PCI Is a Good Option for Patients With Complex Coronary Artery Disease 3American Lung Association Study Finds No Evidence of Depression or Suicide Linked to Asthma and Allergy Drug Montelukast 2American Lung Association Study Finds No Evidence of Depression or Suicide Linked to Asthma and Allergy Drug Montelukast 3
(Date:11/27/2009)...d cycling plus low-emission vehicles may reduce fu... FRIDAY, Nov. 27 (HealthDay News) -- Encouraging c...cars would offer much greater public health benefi....K. researchers have found. , The study compare...ive urban land transport scenarios for London, Eng...
(Date:11/27/2009)... Multi-purpose bilingual coloring b...for use by the business community to educate - inf...jects from Safety issues to Dinosuars to ABC,S and... Saint Louis, MO (PRWEB) November 27, 2009 -- Tod...cs or toys to keep them busy any hour of the day, ...
(Date:11/26/2009)..., PRINCETON, N.J., Nov. 27 The d...t double over the next 25 years and annual medical...billion, up from $113 billion today, according to ...es Care . The National Changing Diabetes ® ...ioned the analysis by a team from the University o...
(Date:11/26/2009)... bigger thrill when on an emotional rollercoaster,...thDay News) -- Call it the fear factor meets the j... spectators -- especially those who root for the w...it,s a closely contested match and victory was in ...r. , Chew on that this Thanksgiving weekend as ...
(Date:11/26/2009)... Benton Communications announces a ...h system for retailers struggling to make an econo...ovember 26, 2009 -- Flu fears is the type of chall...mergency room, according to Dr. David Benton, busi...d business growth system – The Rfactor Inte...
Breaking Medicine News(10 mins):Health News:More Foot Power, Less Car Pollution Best for Health 2Health News:Really Big Coloring Books Debuts Bi-Lingual Spanish-English Line of Custom and Imprintable Coloring Books 2Health News:Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows 2Health News:Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows 3Health News:Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows 4Health News:Watching the Nail-Biting Big Game Hurts So Good 2Health News:Watching the Nail-Biting Big Game Hurts So Good 3Health News:Pharmacist Injects Cure for Ailing Businesses 2
...ril 21, 2009 , , Noon Central Time , , Aurora...Biorepository & Informatics Technology , , M...-Source Robotic Biorepository & Informatics Te...des a, library of blood samples and...
...ovides 99.99 Percent Reduction of Many Dangerous P...- Union Springs Pharmaceuticals, LLC today announ...uct, MyClyns, a portable spray that reduces 99.99 ..., which is a critical component to effective, port...
...April 15 Cardium Therapeutics (NYSE Amex: CXM )... compliance plan which has been accepted by the NY..., , (Logo: http://www.newscom.com/cgi-bin/prnh/...that the company was considered to be noncompliant...
... New FDA-Approved Medical Device Obje...e Patient Functional Capacity, Therapy Response an...Paul, MN (PRWeb) April 14, 2009 -- Dr. Dean A. Bra...cal Lipidology, and an Assistant Consulting Profes...
... buck an industry trend and boost enrollments , ,...onomy struggles, many health and fitness clubs con...ranchisees of Planet Fitness, however, the fastest...hips totaling in the six figures. , , The campaig...
....J., April 15 An estimated 1,000 lives could be s...aster emergency care during and immediately after ...could mean the difference between saving a life ..... the pre-hospital setting, thereby making St. Jose...
Other Medicine News:Health News:Groundbreaking First Response Spray Now Available in Europe 2Health News:Cardium Provides Update Regarding Exchange Listing Compliance Plan Accepted by NYSE Amex 2Health News:Cardium Provides Update Regarding Exchange Listing Compliance Plan Accepted by NYSE Amex 3Health News:Cardium Provides Update Regarding Exchange Listing Compliance Plan Accepted by NYSE Amex 4Health News:Cardium Provides Update Regarding Exchange Listing Compliance Plan Accepted by NYSE Amex 5Health News:Florida Cardiologist First in United States to Acquire Innovative Shape-HF Cardiopulmonary Testing System 2Health News:Florida Cardiologist First in United States to Acquire Innovative Shape-HF Cardiopulmonary Testing System 3Health News:Despite Ailing Economy, Planet Fitness Thrives 2Health News:St. Joseph's Healthcare System Becomes First Hospital in the Region to Implement Pre-Hospital Therapeutic Cooling to Save the Lives of Cardiac Arrest Patients 2Health News:St. Joseph's Healthcare System Becomes First Hospital in the Region to Implement Pre-Hospital Therapeutic Cooling to Save the Lives of Cardiac Arrest Patients 3
GluStitch® Monograph
Affinity™ DC Pacemakers
Affinity DR 5330R
... 1688 and model 1488 active-fixation leads are amo...ing leads, offering the unsurpassed handling advan... Jude Medical's line of active-fixation leads. Imp...iameter of the Tendril SDX lead is designed to low...
Medicine Products: